Literature DB >> 16695986

p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event.

D C Mangham1, A Cannon, X Q Li, S Komiya, M C Gebhardt, D S Springfield, A E Rosenberg, H J Mankin.   

Abstract

Aim-To determine the presence of p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumours (ETs) and to assess whether p53 accumulation has any prognostic value.Methods-From a prospectively compiled database of 76 patients with ETs, suitable tumour tissue was available for 38. The monoclonal antibody pAb1801 was used to detect p53 nuclear protein overexpression. Results-Nuclear staining was detected in the tumours of three (8%) of the 38 patients. Where tumours stained positively, over 10% of the tumour nuclei were postively stained. All three patients whose tumours overexpressed p53 died and in a relatively short time compared with the patients who did not overexpress p53 (mean 3.7 months compared with a mean of 38.7 months in the p53 negative group).Conclusion-Overexpression of p53 in ETs is an uncommon event. Overexpression of p53 has repeatedly been shown to correlate closely with p53 point missense mutations and therefore this oncogenic event appears not to be of primary pathogenic importance in ETs. There is a tentative indication that those uncommon ETs in which p53 overexpression can be detected may be-have more aggressively.

Entities:  

Year:  1995        PMID: 16695986      PMCID: PMC407929          DOI: 10.1136/mp.48.2.m79

Source DB:  PubMed          Journal:  Clin Mol Pathol        ISSN: 1355-2910


  28 in total

1.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.

Authors:  J Toguchida; T Yamaguchi; B Ritchie; R L Beauchamp; S H Dayton; G E Herrera; T Yamamuro; Y Kotoura; M S Sasaki; J B Little
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

2.  Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.

Authors:  M R Stratton; S Moss; W Warren; H Patterson; J Clark; C Fisher; C D Fletcher; A Ball; M Thomas; B A Gusterson
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

3.  Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.

Authors:  J M Varley; W J Brammar; D P Lane; J E Swallow; C Dolan; R A Walker
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

4.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

5.  Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.

Authors:  K Devaney; T N Vinh; D E Sweet
Journal:  Hum Pathol       Date:  1993-11       Impact factor: 3.466

6.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas.

Authors:  E Campo; O de la Calle-Martin; R Miquel; A Palacin; M Romero; V Fabregat; J Vives; A Cardesa; J Yague
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  4 in total

1.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Daniel M Lerman; Michael J Monument; Elizabeth McIlvaine; Xiao-qiong Liu; Dali Huang; Laura Monovich; Natalie Beeler; Richard G Gorlick; Neyssa M Marina; Richard B Womer; Julia A Bridge; Mark D Krailo; R Lor Randall; Stephen L Lessnick
Journal:  Pediatr Blood Cancer       Date:  2014-12-02       Impact factor: 3.167

Review 3.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

Review 4.  An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.

Authors:  David S Shulman; Sarah B Whittle; Didier Surdez; Kelly M Bailey; Enrique de Álava; Jason T Yustein; Adam Shlien; Masanori Hayashi; Alexander J R Bishop; Brian D Crompton; Steven G DuBois; Neerav Shukla; Patrick J Leavey; Stephen L Lessnick; Heinrich Kovar; Olivier Delattre; Thomas G P Grünewald; Cristina R Antonescu; Ryan D Roberts; Jeffrey A Toretsky; Franck Tirode; Richard Gorlick; Katherine A Janeway; Damon Reed; Elizabeth R Lawlor; Patrick J Grohar
Journal:  NPJ Precis Oncol       Date:  2022-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.